Mutational spectrum of de novo NPM1-mutated acute myeloid leukemia patients older than 75 years

References

• Ley TJ, Miller C, Ding L, Cancer Genome Atlas Research N, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–2074.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127(1):29–41.
   PubMed Web of Science ®Google Scholar
• Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593–606.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.
   PubMed Web of Science ®Google Scholar
• Shlush LI, Zandi S, Mitchell A, HALT Pan-Leukemia Gene Panel Consortium, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506(7488):328–333.
   PubMed Web of Science ®Google Scholar
• Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9–16.
   PubMed Web of Science ®Google Scholar
• Swerdlow SC, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2017.
   Google Scholar
• Chou WC, Tang JL, Lin LI, et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res. 2006;66(6):3310–3316.
   PubMed Web of Science ®Google Scholar
• Falini B, Martelli MP, Bolli N, et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood. 2011;117(4):1109–1120.
   PubMed Web of Science ®Google Scholar
• Falini B, Mecucci C, Tiacci E, GIMEMA Acute Leukemia Working Party, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254–266.
   PubMed Web of Science ®Google Scholar
• Falini B, Nicoletti I, Martelli MF, et al. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc + AML): biologic and clinical features. Blood. 2007;109(3):874–885.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Jadersten M, Deneberg S, et al. The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. Blood Adv. 2020;4(6):1094–1101.
   PubMed Web of Science ®Google Scholar
• Thiede C, Koch S, Creutzig E, 0for the Deutsche Studieninitiative Leukämie (DSIL), et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107(1):4011–4020.
   PubMedGoogle Scholar
• National Cancer Institute. Surveillance, Epidemiology, and End Results Program, 2020. [cited 2021 Feb 24]. Available from: http://seer.cancer.gov/.
   Google Scholar
• Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179–4187.
   PubMed Web of Science ®Google Scholar
• Juliusson G. Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry. Clin Lymphoma Myeloma Leuk. 2011;11(Suppl 1):S54–S59.
   PubMedGoogle Scholar
• Juliusson G, Hagberg O, Lazarevic VL, et al. Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. Blood. 2019;134(18):1558–1561.
   PubMed Web of Science ®Google Scholar
• Lazarevic VL, Bredberg A, Lorenz F, Swedish AML Registry, et al. Acute myeloid leukemia in very old patients. Haematologica. 2018;103(12):e578–e580.
   PubMed Web of Science ®Google Scholar
• Angenendt L, Rollig C, Montesinos P, et al. Chromosomal abnormalities and prognosis in NPM1-mutated acute myeloid leukemia: a pooled analysis of individual patient data from nine international cohorts. J Clin Oncol. 2019;37(29):2632–2642.
   PubMed Web of Science ®Google Scholar
• Prassek VV, Rothenberg-Thurley M, Sauerland MC, et al. Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. Haematologica. 2018;103(11):1853–1861.
   PubMed Web of Science ®Google Scholar
• Pettersson L, Leveen P, Axler O, et al. Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia. Genes Chromosomes Cancer. 2016;55(10):750–766.
   PubMed Web of Science ®Google Scholar
• Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv preprint arXiv: 13033997v1[q-bioGN] 2013.
   Google Scholar
• Garrison E MG. Haplotype-based variant detection from short-read sequencing. arXiv preprint arXiv:12073907v2 [q-bioGN] 2012.
   Google Scholar
• Benjamin D, Sato T, Cibulskis K, et al. Calling Somatic SNVs and Indels with Mutect2. bioRxiv 2019:861054.
   Google Scholar
• Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47(D1):D941–D947.
   PubMed Web of Science ®Google Scholar
• Smigielski EM, Sirotkin K, Ward M, et al. dbSNP: a database of single nucleotide polymorphisms. Nucleic Acids Res. 2000;28(1):352–355.
   PubMed Web of Science ®Google Scholar
• Ye K, Schulz MH, Long Q, et al. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics. 2009;25(21):2865–2871.
   PubMed Web of Science ®Google Scholar
• Ivey A, Hills RK, Simpson MA, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374(5):422–433.
   PubMed Web of Science ®Google Scholar
• Renaud L, Nibourel O, Marceau-Renaut A, et al. Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: a study of the French Hauts-de-France AML observatory. Am J Hematol. 2019;94(1):E24–E27.
   PubMed Web of Science ®Google Scholar
• Liu YR, Zhu HH, Ruan GR, et al. NPM1-mutated acute myeloid leukemia of monocytic or myeloid origin exhibit distinct immunophenotypes. Leuk Res. 2013;37(7):737–741.
   PubMed Web of Science ®Google Scholar
• Mason EF, Kuo FC, Hasserjian RP, et al. A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome. Am J Hematol. 2018;93(4):504–510.
   PubMed Web of Science ®Google Scholar
• Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367–1376.
   PubMed Web of Science ®Google Scholar
• Hulegardh E, Nilsson C, Lazarevic V, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015;90(3):208–214.
   PubMed Web of Science ®Google Scholar
• Metzeler KH, Herold T, Rothenberg-Thurley M, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128(5):686–698.
   PubMed Web of Science ®Google Scholar
• Silva P, Neumann M, Schroeder MP, et al. Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape. Leukemia. 2017;31(7):1640–1644.
   PubMed Web of Science ®Google Scholar
• Mason EF, Hasserjian RP, Aggarwal N, et al. Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome. Blood Adv. 2019;3(21):3322–3332.
   PubMed Web of Science ®Google Scholar
• Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424–2433.
   PubMed Web of Science ®Google Scholar
• Park DJ, Kwon A, Cho BS, et al. Characteristics of DNMT3A mutations in acute myeloid leukemia. Blood Res. 2020;55(1):17–26.
   PubMed Web of Science ®Google Scholar
• Kumar D, Mehta A, Panigrahi MK, et al. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations. Hematol Oncol Stem Cell Ther. 2018;11(2):82–89.
   PubMedGoogle Scholar
• Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488–2498.
   PubMed Web of Science ®Google Scholar
• Morita K, Wang F, Jahn K, et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020;11(1):5327.
   PubMed Web of Science ®Google Scholar
• Toth LN, Green D, Peterson J, et al. Variant allele frequencies do not correlate well with myeloblast counts in a clinically validated gene sequencing panel for routine acute myeloid leukemia workup. Leuk Lymphoma. 2019;60(10):2415–2422.
   PubMed Web of Science ®Google Scholar